Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the drug developer's shares up nearly 42%, as it aims to win approval for the ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. Damian Garde is a reporter at ...

The EA-37B is meant to disrupt enemy communications, playing havoc on their command and control and shattering their kill chains.

Larger than the Jeep Renegade but smaller than the Cherokee, the Compass is sized to fit between the subcompact and compact SUV segments. The current second-generation Compass was introduced for the ...

The car-like 2012 Jeep Compass is the only crossover vehicle in the Jeep family, and shares a platform with the boxy Jeep Patriot. The Compass combines the utility of a compact SUV and the ...

Frankly, the Jeep Compass has failed to impress us. Sweeping updates applied for 2022 help slightly, but not much. The Compass slots between the diminutive Renegade and the compact Cherokee in Jeep's ...

Tracking fitness and health doesn’t have to involve wearing a big screen on your wrist. With the rise of smart rings, screenless bands, and advanced hybrid smartwatches, you can now discreetly and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

If making a budget is daunting, there are apps that can do the grunt work for you. A good budgeting app can save you time and energy while helping you to spend smarter and save more. CNBC Select ...

Positive results from the second of two phase III trials set Compass Pathways plc’s synthetic psilocybin treatment, COMP-360, on track for a potential U.S. FDA approval within a year as the first ...

DBC – Invesco DB Commodity Tracking – Check DBC price, review total assets, see historical growth, and review the analyst rating from Morningstar.